Zobrazeno 1 - 10
of 57
pro vyhledávání: '"13-valent pneumococcal conjugate vaccine (PCV13)"'
Autor:
John M. McLaughlin, David L. Swerdlow, Farid Khan, Oliver Will, Aaron Curry, Vincenza Snow, Raul E. Isturiz, Luis Jodar
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 4, Pp 841-849 (2019)
Background: In September 2014, 13-valent pneumococcal conjugate vaccine (PCV13) was universally recommended for all US adults aged ≥65 years. Adult PCV13 coverage, including whether disparities in uptake exist, however, is not well-described. Metho
Externí odkaz:
https://doaj.org/article/81e189dc97c64eb6b52bdf6b21650442
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 3, Pp 584-593 (2019)
Thirteen-valent pneumococcal conjugate vaccine (PCV13) was licensed in adults to address the unmet medical need of vaccine-type community acquired pneumonia (CAP) and the limitations of previous plain-polysaccharide vaccines. Since then, some have qu
Externí odkaz:
https://doaj.org/article/8394bcf840114badaf12e310185827ab
Publikováno v:
Emerging Infectious Diseases, Vol 22, Iss 6, Pp 1109-1112 (2016)
Introduction of pneumococcal conjugate vaccines in the childhood immunization schedule was associated with decreases in all-cause pneumonia hospitalizations among black and white children in Tennessee, USA. Although racial disparities that existed be
Externí odkaz:
https://doaj.org/article/2618896c2f9d43559187371b43e6d01d
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
M. V. Fedoseenko, D. A. Novikova, N. E. Tkachenko, M. I. Broeva, T. A. Grechukha, A. G. Gaivoronskaya, V. V. Chernikov
Publikováno v:
Педиатрическая фармакология, Vol 11, Iss 5, Pp 59-64 (2014)
Compulsory use of the 7-valent pneumococcal conjugate vaccine in the framework of national pediatric immunization schedules of the developed countries resulted in significant decrease in the prevalence of the pneumococcal infections induced by the va
Externí odkaz:
https://doaj.org/article/5a35145f8c1c4b64a74ef574e952692e
Publikováno v:
BMC Immunology, Vol 20, Iss 1, Pp 1-13 (2019)
BMC Immunology
BMC Immunology
Background While the 23-valent pneumococcal polysaccharide vaccine (PPV23) is routinely used in Canada and some other countries to prevent pneumococcal infection in adults with chronic kidney disease (CKD), patients develop a suboptimal antibody resp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fbf36fe52b81a1ac16a0e797c1390f4
http://link.springer.com/article/10.1186/s12865-019-0325-9
http://link.springer.com/article/10.1186/s12865-019-0325-9
Publikováno v:
Human Vaccines & Immunotherapeutics
Thirteen-valent pneumococcal conjugate vaccine (PCV13) was licensed in adults to address the unmet medical need of vaccine-type community acquired pneumonia (CAP) and the limitations of previous plain-polysaccharide vaccines. Since then, some have qu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c8e784048614019991d6ea2066afb9a
http://europepmc.org/articles/PMC6605720
http://europepmc.org/articles/PMC6605720
Autor:
Luis Jodar, John M McLaughlin, Vincenza Snow, Aaron Curry, Oliver Will, Farid Khan, Raul E Isturiz, David L. Swerdlow
Publikováno v:
Human Vaccines & Immunotherapeutics
Background: In September 2014, 13-valent pneumococcal conjugate vaccine (PCV13) was universally recommended for all US adults aged ≥65 years. Adult PCV13 coverage, including whether disparities in uptake exist, however, is not well-described. Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4c7b4a8b9fcb86e60c5aedbb6819f9d
https://pubmed.ncbi.nlm.nih.gov/30676236
https://pubmed.ncbi.nlm.nih.gov/30676236
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Emerging Infectious Diseases, Vol 22, Iss 6, Pp 1109-1112 (2016)
Emerging Infectious Diseases
Emerging Infectious Diseases
Introduction of pneumococcal conjugate vaccines in the childhood immunization schedule was associated with decreases in all-cause pneumonia hospitalizations among black and white children in Tennessee, USA. Although racial disparities that existed be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fab7e99d17d96bb0992422aea818a48
https://wwwnc.cdc.gov/eid/article/22/6/15-2023_article
https://wwwnc.cdc.gov/eid/article/22/6/15-2023_article